Strides gets tentative FDA nod for HIV/AIDS
This article was originally published in Scrip
Executive Summary
Strides Arcolab has received tentative approval from the US FDA for its new drug application (NDA) for a fixed-dose combination of lamivudine plus stavudine tablets 150mg/30mg under the President's Emergency Plan for AIDS Relief (Pepfar). Strides now has 11 NDA/ANDA approvals under the Pepfar programme.